Axsome Therapeutics AXSM CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's capex?
- Axsome Therapeutics (AXSM) reported capex of $121K in Q1 2026.
- How has Axsome Therapeutics's capex changed year-over-year?
- Axsome Therapeutics's capex decreased by 64.2% year-over-year, from $338K to $121K.
- What is the long-term trend for Axsome Therapeutics's capex?
- Over 4 years (2021 to 2025), Axsome Therapeutics's capex has grown at a 11.7% compound annual growth rate (CAGR), from $308K to $480K.
- What does capex mean?
- Cash spent on long-term physical assets like equipment or facilities.
- How do you interpret capex?
- High spending indicates investment in future capacity, while low spending may indicate asset-light operations or deferred maintenance.
- How does capex compare across companies?
- Varies by business model; biopharma companies may have low CapEx if they outsource manufacturing, or high CapEx if they build internal facilities.